Sentinel lymph node assessment in breast cancer-an update on current recommendations.
Gábor CserniAoife MaguireSimonetta BianchiAleš RyškaAnikó KovacsPublished in: Virchows Archiv : an international journal of pathology (2021)
Sentinel lymph node biopsy (SLNB) has become the preferred method of surgical pathological nodal staging of early breast cancer by the end of the nineties. As the most likely sites of metastasis, the SLNs allow a more precise staging, and indeed gross sectioning, step sectioning, immunohistochemistry, and molecular staging methods have been used to disclose metastatic involvement of these lymph nodes. This review summarizes the backgrounds of SLNB, trends in related surgery and pathology. It also gives an insight into European National recommendations related to SLN and divergent daily practices in European pathology departments, on the basis of replies to questionnaires from 84 pathologists from 38 European countries. The questionnaires revealed the post-neoadjuvant setting as an area where a significant minority of pathologists report less confidence in classifying residual nodal involvement into TNM categories. The review also summarizes the neoadjuvant therapy-related aspects of SLNB.
Keyphrases
- lymph node
- sentinel lymph node
- neoadjuvant chemotherapy
- squamous cell carcinoma
- small cell lung cancer
- primary care
- early breast cancer
- minimally invasive
- clinical practice
- early stage
- rectal cancer
- quality improvement
- ultrasound guided
- locally advanced
- psychometric properties
- single cell
- cell therapy
- drug induced
- breast cancer risk